Symbols

Symbols

OTLK

OTLK

Outlook Therapeutics Resubmits BLA for ONS-5010 Wet AMD Treatment

Outlook Therapeutics Resubmits Biologics License Application for ONS-5010 Ophthalmic Bevacizumab Formulation.

Tuesday Sep 30, 2025

HC Wainwright & Co. Reaffirms Neutral Rating for Outlook Therapeutics with $1.00 Price Target

Outlook Therapeutics: HC Wainwright Raises PT to $1, Reiterates Neutral Rating

Monday Sep 29, 2025

Outlook Therapeutics Expects BLA Resubmission Before End of 2025

Outlook Therapeutics Updates on FDA Meeting for ONS-5010/LYTENAVA

Outlook Therapeutics Completes Type A Meeting with FDA on ONS-5010 BLA Resubmission.

Friday Sep 26, 2025

Outlook Therapeutics, Inc. shares fall 1.95% premarket as Wall Street futures mixed ahead of inflation data.

Monday Sep 22, 2025

Ascendiant Capital maintains Buy on Outlook Therapeutics, lowers PT to $8.

Thursday Sep 04, 2025

BriaCell's 15-min chart indicates a bearish KDJ Death Cross and Marubozu.

Wednesday Sep 03, 2025

Outlook Therapeutics shares fall 1.61% intraday after requesting a meeting with the US FDA.

Outlook Therapeutics presents at EURETINA Congress on bevacizumab treatment.

Outlook Therapeutics to Present at EURETINA Innovation Spotlight

Tuesday Sep 02, 2025

Outlook Therapeutics shares rise 1.65% intraday after requesting a Type A meeting with the FDA to discuss ONS-5010.

Outlook Therapeutics Submits Type A Meeting Request to FDA.

Outlook Therapeutics Seeks FDA Clarification on Confirmatory Evidence for ONS-5010 Approval

Friday Aug 29, 2025

Guggenheim Downgrades Outlook Therapeutics to Neutral, Maintains No Price Target

Outlook Therapeutics Receives CRL for Lytenava, Chardan Calls it a "Significant Setback"

Chardan Capital Maintains Neutral Rating for Outlook Therapeutics with $3.00 Price Target.

Outlook Therapeutics Downgraded to Hold by H.C. Wainwright Analyst